List view / Grid view

cytotoxicity

 

article

Challenges in developing robust potency assays for ADCs

18 August 2025 | By

Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…

article

Strategic planning in ADC development: insights from Lonza

2 June 2025 | By

Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.